NewAmsterdam Pharma Company N.V. has grown revenue −40% a year over three years and −40% a year over five. Revenue growth, 3-year annual rate: −40% (Biotechnology median +17%). Revenue growth, 5-year rate: −40%, growth has slowed since the five-year average. Years of annual history on file: 5, FY2021 to FY2025, as filed.

NAMSNewAmsterdam Pharma Company N.V.

Healthcare

$21.58-19% 1Y

$21.58

$21.1452 weeks$41.45

Is it growing?

Watch

Growth is fading: revenue shrinking (−89% year on year) and operating margin narrowing (−55695.6 points).

2 to watch, 1 without data

Revenue trend−89% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings.

Margin direction−55695.6 points operating

Trailing-twelve-month operating margin, -56426.9% now against -731.2% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is NAMS growing?

NewAmsterdam Pharma Company N.V. has grown revenue −40% a year over three years and −40% a year over five.

−40%

Revenue growth, 3-year annual rate · Biotechnology median +17% · shrinking · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: −40%
Revenue growth, 5-year rate · −40% over three · growth has slowed since the five-year average
Years of annual history on file: 5
Years of annual history on file · FY2021 to FY2025, as filed

Details›